Analysis of the Strong Performance of Jindike (688670)

Jindike (688670), as Jiangsu Jindike Biotechnology Co., Ltd., its recent strong performance is mainly due to the superposition of multiple factors. The company focuses on the R&D, production, and sales of human vaccines, with its core product being the quadrivalent influenza virus split vaccine [1].

: The company’s revenue in the first three quarters of 2025 increased significantly by 91.93%, showing a strong business recovery trend [2]. This performance growth mainly benefited from the seasonal surge in demand for influenza vaccines. The peak vaccination period for the 2025 flu season has arrived, and some regions even experienced supply shortages [5]. At the same time, the company’s quadrivalent influenza virus split vaccine (children’s) project is undergoing Phase III clinical trials, with continuous increases in R&D investment, providing new growth points for future growth [1].

: On November 14, Jindike’s stock price rose by the daily limit of 19.99%, closing at 28.03 yuan, with a net inflow of 40.3234 million yuan from main funds [2]. This capital inflow reflects the market’s positive expectations for the company’s prospects. The company was also selected as one of the 695 stocks that broke their annual highs in a week, becoming a hot spot of market attention [4].

: The biopharmaceutical vaccine sector has recently received key attention from market funds, forming a sector rotation effect [3]. Under the dual influence of cooling temperatures and flu, pharmaceutical stocks have attracted capital attention, the anti-flu concept has broken out against the market trend, and many pharmaceutical stocks have risen strongly by the daily limit [6][7].

: The influenza vaccine industry has obvious seasonal characteristics, with the peak vaccination period in autumn and winter every year. The upward trend of the flu epidemic in 2025 has created a favorable market environment for vaccine companies [5].

: The progress of the Phase III clinical trial of the children’s influenza vaccine is an important value catalyst for the company. If the trial is successful, it will significantly expand the company’s target market scope, extending from the adult market to the children’s market, bringing greater growth space [1].

: Although the price war of quadrivalent influenza vaccines has had a certain impact on market expectations, Jindike still maintains a relative advantage in industry competition due to its technical advantages and market position [2].

:

• Sustained growth in demand for influenza vaccines, especially the potential demand in the children’s market
• New product opportunities brought by R&D pipeline progress
• Valuation repair opportunities brought by sector rotation effects

:

• Intensified price competition for influenza vaccines may affect profitability
• R&D projects have uncertainties, and clinical trial results have risks
• Seasonal business characteristics may lead to performance fluctuations

: Based on the current flu epidemic situation and the company’s fundamental improvement, the strong performance is expected to continue in the short term. However, long-term sustainability needs to pay attention to R&D progress, changes in the industry competitive landscape, and the continuous improvement of the company’s performance.

Jindike’s recent strong performance is the comprehensive result of fundamental improvement, industry prosperity enhancement, and capital-driven factors. The company’s revenue increased significantly by 91.93% showing a strong recovery momentum [2], and the seasonal surge in demand for influenza vaccines provided support for performance [5]. The positive inflow of main funds and the sector rotation effect further amplified the driving force of the stock price rise [2][3]. Investors should pay attention to the progress of the company’s Phase III clinical trial of the children’s influenza vaccine, which will be a key factor affecting the company’s long-term value [1].